{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T13:43:51Z","timestamp":1783691031772,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":2442,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100005002","name":"California Department of Public Health","doi-asserted-by":"crossref","award":["103885"],"award-info":[{"award-number":["103885"]}],"id":[{"id":"10.13039\/100005002","id-type":"DOI","asserted-by":"crossref"}]},{"name":"of NCI","award":["N01-PC-35136"],"award-info":[{"award-number":["N01-PC-35136"]}]},{"name":"Northern California Cancer Center","award":["N01-PC-35139"],"award-info":[{"award-number":["N01-PC-35139"]}]},{"DOI":"10.13039\/100006034","name":"University of Southern California","doi-asserted-by":"crossref","award":["N02-PC-15105"],"award-info":[{"award-number":["N02-PC-15105"]}],"id":[{"id":"10.13039\/100006034","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001808","name":"Public Health Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001808","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Centers for Disease Control and Prevention's National Program of Cancer Registries","award":["#U55\/CCR921930-02"],"award-info":[{"award-number":["#U55\/CCR921930-02"]}]},{"DOI":"10.13039\/100001808","name":"Public Health Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001808","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1093\/annonc\/mds644","type":"journal-article","created":{"date-parts":[[2013,1,25]],"date-time":"2013-01-25T02:42:00Z","timestamp":1359081720000},"page":"1352-1359","source":"Crossref","is-referenced-by-count":33,"title":["Comparative outcomes of oncologic therapy in gastric extranodal marginal zone (MALT) lymphoma: analysis of the SEER-Medicare database"],"prefix":"10.1016","volume":"24","author":[{"given":"A.J.","family":"Olszewski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mds644_bb0010","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cgh.2009.07.017","article-title":"Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma","volume":"8","author":"Zullo","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1093\/annonc\/mds644_bb0015","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s12032-009-9207-y","article-title":"Treatment of low-grade gastric MALT-lymphoma unresponsive to Helicobacter pylori therapy: a pooled-data analysis","volume":"27","author":"Zullo","year":"2010","journal-title":"Med Oncol"},{"issue":"Suppl 4","key":"10.1093\/annonc\/mds644_bb0020","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/annonc\/mdp146","article-title":"Gastric marginal zone lymphoma of MALT type: ESMO clinical recommendations for diagnosis, treatment and follow-up","volume":"20","author":"Zucca","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds644_bb0025","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/gut.2010.224949","article-title":"EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT","volume":"60","author":"Ruskone-Fourmestraux","year":"2011","journal-title":"Gut"},{"key":"10.1093\/annonc\/mds644_bb0030","doi-asserted-by":"crossref","first-page":"IV-3","DOI":"10.1097\/00005650-200208001-00002","article-title":"Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population","volume":"40","author":"Warren","year":"2002","journal-title":"Med Care"},{"key":"10.1093\/annonc\/mds644_bb0035","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/jnci\/dji189","article-title":"Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants","volume":"97","author":"Lamont","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mds644_bb0040","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1182\/blood-2010-08-301929","article-title":"An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemia","volume":"117","author":"Danese","year":"2011","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds644_bb0045","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1182\/blood-2011-04-348367","article-title":"Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma","volume":"118","author":"Griffiths","year":"2011","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds644_bb0050","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1093\/annonc\/mdr486","article-title":"An observational study of the prevalence and incidence of comorbid conditions in older women with breast cancer","volume":"23","author":"Danese","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds644_bb0055","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0895-4356(00)00256-0","article-title":"Development of a comorbidity index using physician claims data","volume":"53","author":"Klabunde","year":"2000","journal-title":"J Clin Epidemiol"},{"key":"10.1093\/annonc\/mds644_bb0060","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1200\/JCO.2009.25.4052","article-title":"Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer","volume":"28","author":"Davidoff","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds644_bb0065","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1002\/sim.1203","article-title":"Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects","volume":"21","author":"Royston","year":"2002","journal-title":"Stat Med"},{"key":"10.1093\/annonc\/mds644_bb0070","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1200\/JCO.2007.12.9866","article-title":"Choice and interpretation of statistical tests used when competing risks are present","volume":"26","author":"Dignam","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds644_bb0075","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"10.1093\/annonc\/mds644_bb0080","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"10.1093\/annonc\/mds644_bb0085","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"10.1093\/annonc\/mds644_bb0090","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00001648-200009000-00012","article-title":"Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men","volume":"11","author":"Hernan","year":"2000","journal-title":"Epidemiology"},{"key":"10.1093\/annonc\/mds644_bb0095","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1093\/aje\/kwq198","article-title":"Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution\u2014a simulation study","volume":"172","author":"Sturmer","year":"2010","journal-title":"Am J Epidemiol"},{"key":"10.1093\/annonc\/mds644_bb0100","article-title":"Survival of patients with marginal zone lymphoma: analysis of the Surveillance, Epidemiology, and End Results database","author":"Olszewski","year":"2012","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mds644_bb0105","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1136\/gutjnl-2011-300495","article-title":"Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan","volume":"61","author":"Nakamura","year":"2012","journal-title":"Gut"},{"key":"10.1093\/annonc\/mds644_bb0110","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1365-2141.2008.07486.x","article-title":"Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial","volume":"144","author":"Hancock","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mds644_bb0115","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdl468","article-title":"Role of radiation therapy in the treatment of stage I\/II mucosa-associated lymphoid tissue lymphoma","volume":"18","author":"Tsai","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds644_bb0120","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.1200\/JCO.2003.06.085","article-title":"Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome","volume":"21","author":"Tsang","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds644_bb0125","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1200\/JCO.2005.08.128","article-title":"Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy","volume":"23","author":"Martinelli","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds644_bb0130","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1200\/JCO.2002.05.117","article-title":"Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study","volume":"20","author":"Jager","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds644_bb0135","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1002\/cncr.24605","article-title":"Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type","volume":"115","author":"Salar","year":"2009","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mds644_bb0140","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1385\/MO:22:1:057","article-title":"Mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach: results of a controlled clinical trial","volume":"22","author":"Aviles","year":"2005","journal-title":"Med Oncol"},{"key":"10.1093\/annonc\/mds644_bb0145","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/j.1365-2141.2009.07677.x","article-title":"A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas","volume":"145","author":"Brown","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mds644_bb0150","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00277-011-1337-6","article-title":"Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study","volume":"91","author":"Kang","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1093\/annonc\/mds644_bb0155","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1182\/blood-2002-11-3496","article-title":"Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type","volume":"102","author":"Conconi","year":"2003","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds644_bb0160","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/jnci\/dji277","article-title":"Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma","volume":"97","author":"Chen","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mds644_bb0165","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1093\/annonc\/mdn760","article-title":"Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type","volume":"20","author":"Stathis","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds644_bb0170","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S0002-9440(10)65012-2","article-title":"The product of the t(11;18), an API2-MLT fusion, marks nearly half of gastric MALT type lymphomas without large cell proliferation","volume":"156","author":"Baens","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1093\/annonc\/mds644_bb0175","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1136\/gut.2007.123729","article-title":"Clinical impact of genetic aberrations in gastric MALT lymphoma: a comprehensive analysis using interphase fluorescence in situ hybridisation","volume":"56","author":"Nakamura","year":"2007","journal-title":"Gut"},{"key":"10.1093\/annonc\/mds644_bb0180","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1080\/10428190600709226","article-title":"Primary gastrointestinal non-Hodgkin's lymphoma: a clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG)","volume":"47","author":"Papaxoinis","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mds644_bb0185","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1136\/gut.39.4.556","article-title":"Primary non-Hodgkin lymphoma of the stomach: endoscopic pattern and prognosis in low versus high grade malignancy in relation to the MALT concept","volume":"39","author":"Taal","year":"1996","journal-title":"Gut"},{"key":"10.1093\/annonc\/mds644_bb0190","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1155\/2012\/480160","article-title":"Increasing incidence rates, distribution and histological characteristics of primary gastrointestinal non-Hodgkin lymphoma in a North American population","volume":"26","author":"Howell","year":"2012","journal-title":"Can J Gastroenterol"},{"key":"10.1093\/annonc\/mds644_bb0195","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1158\/1055-9965.EPI-03-0250","article-title":"Expert review of non-Hodgkin's lymphomas in a population-based cancer registry: reliability of diagnosis and subtype classifications","volume":"13","author":"Clarke","year":"2004","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1093\/annonc\/mds644_bb0200","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1111\/j.1475-6773.2004.00321.x","article-title":"Specificity and sensitivity of claims-based algorithms for identifying members of Medicare + Choice health plans that have chronic medical conditions","volume":"39","author":"Rector","year":"2004","journal-title":"Health Serv Res"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419372588?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419372588?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/24\/5\/1352\/13789228\/mds644.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T07:46:21Z","timestamp":1624693581000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419372588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0923753419372588"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mds644","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}